Halting GLP-1 medications can lead to a significant increase in cardiovascular risks, according to a new study involving over 333,000 participants.
Recent research underscores the vital need for continuous use of GLP-1 medications, such as semaglutide (Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound), for individuals managing type 2 diabetes. This class of drugs, which has become increasingly popular for their dual role in diabetes management and weight loss, also provides key cardiovascular benefits that diminish alarmingly once treatment is halted.
A study conducted by investigators at Washington University School of Medicine in St. Louis examined a cohort of over 333,000 U.S. veterans with type 2 diabetes over the course of three years. The findings revealed that instances of major cardiovascular events — including heart attacks and strokes — rose significantly in patients after discontinuing GLP-1 therapy, with the risk increasing notably after just six months off the medication.
The data suggest that those who paused their treatment for a prolonged period (two years or more) faced an alarming 22% higher risk of heart-related issues compared to individuals who maintained their therapy. Not only does this indicate a rapid decline in the cardiovascular protective effects of GLP-1 drugs, but it also points to the necessity of uninterrupted treatment for the ongoing benefits of heart health.
"There's considerable enthusiasm around starting GLP-1 therapies, but we’re not nearly as vigilant about the aftermath of stopping treatment," explained senior author Dr. Ziyad Al-Aly, a clinical epidemiologist at WashU Medicine. He emphasized that many patients discontinue their use due to cost, side effects, or medication shortages, not realizing that the repercussions extend beyond mere weight regain.
When GLP-1 therapy is interrupted, patients may witness a rebound effect, described by Al-Aly as "metabolic whiplash," which exacerbates risk factors like inflammation, blood pressure, and cholesterol levels. While some cardiovascular protection is restored upon resuming treatment, it is often insufficient, indicating that stopping the medication leaves lingering effects.
The study meticulously tracked not just those on GLP-1 therapies but also participants on sulfonylureas, a traditional class of diabetes medications. After reassessing treatment status at six-month intervals, researchers found that nearly a quarter of GLP-1 users experienced at least a six-month treatment break before potentially resuming therapy. The most significant cardiovascular benefit appeared in participants who adhered to GLP-1 medications consistently over the full three years, yielding an 18% lower risk of serious cardiovascular events.
For those who discontinued their GLP-1 therapy before reaching the 18-month mark, the reduction in cardiovascular risk was negligible by study's end when compared to those using sulfonylureas. Treatment gaps highlighted a concerning trend: the longer the break, the lesser the cardiovascular advantages. For example, a one-year hiatus led to a 14% increase in risk, which increased to 22% after two years off the medication.
This swift loss of cardiovascular protection mandates that healthcare providers prioritize adherence to GLP-1 therapy as an essential part of patient management strategies. Al-Aly asserts that doctors should actively encourage consistent medication use, recognizing that GLP-1 drugs are designed for long-term chronic condition management. This includes the need for ongoing conversations about treatment, timely interventions for side effects, and addressing medication costs that can hinder patient compliance.
Moreover, the study emphasizes that while cardiovascular benefits accrue gradually during GLP-1 treatment, their disappearance occurs much more rapidly after discontinuation. The implications are clear: maintaining treatment is crucial for preserving heart health and mitigating the risks associated with type 2 diabetes.
The research, supported by the United States Department of Veterans Affairs, was published in BMJ Medicine. Importantly, the funding body had no influence over the study's design or findings.
Materials provided by Washington University in St. Louis. Note: Content may be edited for style and length.
Stay informed with ScienceDaily's free email newsletter, updated daily and weekly. Or view our many newsfeeds in your RSS reader:
Keep up to date with the latest news from ScienceDaily via social networks:
Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Discussion
Sign in to join the discussion.